Processes of preparing a JAK1 inhibitor and new forms thereto
View Patent ↗This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: as well as new forms of the inhibitor.
1. An anhydrous crystalline form of a compound of Formula Ia:
having an X-ray powder diffraction pattern substantially as shown in FIG. 3 .
2. An anhydrous crystalline form of a compound of Formula Ia:
having an X-ray powder diffraction pattern comprising at least one peak, in terms of 2θ, selected from about 8.8°, about 10.5°, about 16.3°, about 17.5°, about 19.1°, about 21.2°, about 24.0°, and about 26.4°.
3. The anhydrous crystalline form of claim 2 , having an X-ray powder diffraction pattern comprising at least two peaks, in terms of 2θ, selected from about 8.8°, about 10.5°, about 16.3°, about 17.5°, about 19.1°, about 21.2°, about 24.0°, and about 26.4°.
4. The anhydrous crystalline form of claim 2 , having an X-ray powder diffraction pattern comprising at least three peaks, in terms of 2θ, selected from about 8.8°, about 10.5°, about 16.3°, about 17.5°, about 19.1°, about 21.2°, about 24.0°, and about 26.4°.
5. The anhydrous crystalline form of claim 2 , having an X-ray powder diffraction pattern comprising at least four peaks, in terms of 2θ, selected from about 8.8°, about 10.5°, about 16.3°, about 17.5°, about 19.1°, about 21.2°, about 24.0°, and about 26.4°.
6. The anhydrous crystalline form of claim 2 , having an X-ray powder diffraction pattern comprising at least four peaks, in terms of 2θ, selected from about 8.8°, about 16.3°, about 19.1°, about 24.0°, and about 26.4°.
7. The anhydrous crystalline form of claim 2 , having a differential scanning calorimetry thermogram (DSC) substantially as shown in FIG. 1 .
8. The anhydrous crystalline form of claim 2 , having a differential scanning calorimetry thermogram (DSC) characterized by an endothermic peak at about 185° C.
9. The anhydrous crystalline form of claim 2 , having a differential scanning calorimetry thermogram (DSC) characterized by an endothermic peak at about 190° C.
10. The anhydrous crystalline form of claim 2 , having a thermogravimetric analysis thermogram (TGA) substantially as shown in FIG. 2 .
11. The anhydrous crystalline form of claim 2 , having a thermogravimetric analysis thermogram (TGA) characterized by a weight loss of about 1.25% up to 200° C.
12. A composition comprising the anhydrous crystalline form of claim 2 .
13. The composition of claim 12 , wherein the composition comprises at least one pharmaceutically acceptable carrier.